Otros idiomas Neurogene Inc.

Acciones

NGNE

US64135M1053

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 30/04/2024			Varia. Cinco días.	Varia. 1 de enero.
34,48 ^USD	+3,23 %		+10,62 %	+77,92 %

29/04	NEUROGENE INC. : Leerink Partners mantiene su recomendación de compra	ZM
21/03	NEUROGENE INC. : Obtiene una recomendación de compra de William Blair & Co.	ZM

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting	22/04
North American Morning Briefing : Stocks Struggle After New Records	22/03
Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates	18/03
Neurogene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	18/03
North American Morning Briefing : Inflation -2-	15/03
Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial	04/03
Neurogene Inc. Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial	04/03
Neurogene to Participate in Upcoming Investor Conferences	29/02
Neurogene Inc. Appoints Donna Cochener as Senior Vice President, General Counsel	21/02
Neurogene Inc. Appoints Julie Jordan as Chief Medical Officer	17/01
Neurogene Names Julie Jordan as Chief Medical Officer	16/01
Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer	16/01
Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer	16/01
Neurogene Announces Business Update and 2024 Outlook	05/01
Neurogene Announces Business Update and 2024 Outlook	05/01
Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million	20/12
Neurogene Completes Merger With Neoleukin Therapeutics	19/12
Neoleukin Therapeutics : Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome - Form 8-K	19/12
Neoleukin Therapeutics, Inc.(NasdaqCM:NLTX) dropped from NASDAQ Composite Index	18/12
Neurogene Inc. announced that it has received $95 million in funding from a group of investors	18/12

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Neurogene Inc.

Acciones

NGNE

US64135M1053

Otros idiomas

Filtros